Point72 Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Point72 Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$620K	Buy	18,300 +100	+0.5%	+$3.29K	﹤0.01%	3083
2026 Q1	$583K	Buy	+18,200	New	+$593K	﹤0.01%	3055

Other funds holding NAMS

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Point72 Asset Management's NAMS Position: Q2 2026 in Review

Point72 Asset Management opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 168,901 shares worth $5.72M. The stake represents 0.01% of the portfolio and ranks #1665 among its holdings.

194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Point72 Asset Management held 168,901 shares of NewAmsterdam Pharma worth $5.72M as of Q2 2026.
NewAmsterdam Pharma was a new Point72 Asset Management position in Q2 2026.
NewAmsterdam Pharma made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1665 holding.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.